Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) have earned an average rating of “Moderate Buy” from the nine ratings firms that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $11.38.

A number of equities analysts recently issued reports on CMPX shares. Piper Sandler began coverage on Compass Therapeutics in a report on Wednesday, February 19th. They issued an “overweight” rating and a $12.00 target price on the stock. Guggenheim began coverage on shares of Compass Therapeutics in a research note on Monday, February 24th. They issued a “buy” rating and a $12.00 price objective on the stock. D. Boral Capital reissued a “buy” rating and set a $32.00 target price on shares of Compass Therapeutics in a research report on Tuesday, February 25th. Jefferies Financial Group raised their price target on shares of Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Monday, February 10th. Finally, Leerink Partnrs downgraded Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 15th.

Compass Therapeutics Price Performance

CMPX stock opened at $2.69 on Friday. The company’s 50-day moving average is $2.68 and its 200-day moving average is $1.99. The stock has a market capitalization of $371.98 million, a PE ratio of -7.27 and a beta of 1.19. Compass Therapeutics has a 1 year low of $0.77 and a 1 year high of $4.08.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.01). On average, analysts anticipate that Compass Therapeutics will post -0.36 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Compass Therapeutics

Several hedge funds have recently modified their holdings of CMPX. Barclays PLC increased its position in shares of Compass Therapeutics by 195.4% during the third quarter. Barclays PLC now owns 170,245 shares of the company’s stock valued at $314,000 after acquiring an additional 112,614 shares during the last quarter. SG Americas Securities LLC grew its stake in Compass Therapeutics by 921.6% in the 4th quarter. SG Americas Securities LLC now owns 395,017 shares of the company’s stock valued at $573,000 after purchasing an additional 356,352 shares during the period. Geode Capital Management LLC increased its position in shares of Compass Therapeutics by 0.8% during the 3rd quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock valued at $4,251,000 after purchasing an additional 19,095 shares during the last quarter. Bleakley Financial Group LLC raised its stake in shares of Compass Therapeutics by 250.7% during the 4th quarter. Bleakley Financial Group LLC now owns 39,993 shares of the company’s stock worth $58,000 after purchasing an additional 28,589 shares during the period. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Compass Therapeutics in the 3rd quarter worth about $79,000. Institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.